Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VCH-222 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Part A | EXPERIMENTAL | This will be a 4 dose escalation study comparing VCH-222 to placebo treatment. |
| Part B | EXPERIMENTAL | VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks |
| Name | Type | Description |
|---|---|---|
| VCH-222 | DRUG | Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37 |
| telaprevir | DRUG | Tablet, Oral, 1125 mg, q12h, Days 18-37 |
| VCH-222 or matching placebo | DRUG | capsule, oral, 4 doses once daily or twice daily, 3 days |
| peginterferon alfa-2a | BIOLOGICAL | subcutaneous injection, 180 μg, once weekly, 48 weeks |
| ribavirin | DRUG | tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks |
Inclusion Criteria: * Healthy males, and/or healthy females of non-childbearing potential, aged 18 to 55 years (inclusive) * Body mass index (BMI) between 18 and 31 kg/m2 (inclusive) and weight \> 50 kg Exclusion Criteria: * Women of child bearing potential * Subjects positive for Hepatitis B, He...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir |
VCH-222 is an investigational small molecule developed by Vertex Pharmaceuticals for the treatment of hepatitis C, a chronic viral infection of the liver. It has been studied in Phase 1 clinical trials in both healthy volunteers and subjects with chronic hepatitis C infection. It is not an approved therapy.
VCH-222 is being developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. Vertex sponsored the Phase 1 clinical program evaluating the compound in hepatitis C, including drug-drug interaction and multiple ascending dose studies.
VCH-222 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no trials are currently active. The studies enrolled a combined total of 79 participants. VCH-222 is investigational and has not been approved by the FDA for any indication.
VCH-222 has been evaluated in two completed Phase 1 trials. NCT00958152 was a drug-drug interaction study of VCH-222 and telaprevir in 30 healthy subjects in New Zealand. NCT00911963 examined the pharmacokinetics of multiple ascending doses in 49 subjects with chronic hepatitis C infection across the United States, Argentina, Canada, and Puerto Rico.
Both VCH-222 trials were randomized, double-blind, and controlled. NCT00958152 enrolled 30 healthy volunteers aged 18 and older in New Zealand to assess drug-drug interactions with telaprevir. NCT00911963 enrolled 49 adults with chronic hepatitis C infection to evaluate multiple ascending dose pharmacokinetics. No biomarker-based patient selection was used.